Combined therapy with tiotropium and formoterol in chronic obstructive pulmonary disease: Effect on the 6-minute walk test

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 10, Issue 4, 2013, Pages 466-472

  Jayaram, Lata ^a   Wong, Conroy ^b   McAuley, Sue ^b   Rea, Harry ^b,c   Zeng, Irene ^d   O'Dochartaigh, Conor ^b  

^a WESTERN HEALTH   (Australia)

^b MIDDLEMORE HOSPITAL   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d Knowledge and Information Management   (New Zealand)

Author keywords

6 minute walk test; Anticholinergic and long acting beta 2 agonist therapy; Chronic obstructive pulmonary disease

Indexed keywords

CORTICOSTEROID; FORMOTEROL; PLACEBO; TIOTROPIUM BROMIDE;

6 MINUTE WALK TEST; ADD ON THERAPY; ADULT; AGED; ARTICLE; BODY MASS INDEX AIRFLOW OBSTRUCTION DYSPNEA EXERCISE CAPACITY INDEX; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE TEST; EYE DISEASE; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; LUNG FUNCTION; MALE; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SCORING SYSTEM; SKIN DISEASE; SYMPTOM ASSESSMENT; TREATMENT DURATION; URINARY TRACT DISEASE; WALKING;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ETHANOLAMINES; EXERCISE TEST; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SCOPOLAMINE DERIVATIVES; SEVERITY OF ILLNESS INDEX; WALKING;

EID: 84880762634     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2013.771162     Document Type: Article

References (49)

1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Available from: http://www.goldcopd. org/.
2. McKenzie DK, Abramson M, Crockett AJ, Dabscheck E, Glasgow N, Jenkins S, McDonald C, Wood-Baker R, Yang I, Frith PA on behalf of The Australian Lung Foundation. The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease V2.32, 2012.
3. Broad J, Jackson R. Chronic Obstructive Pulmonary Disease and Lung Cancer in New Zealand. Auckland: UniServices; 2003.
4. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58(5):399-404. Epub 2003/05/03.
5. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19(2):209-216. Epub 2002/03/02.
6. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19(2):217-224. Epub 2002/02/28.
7. Grove A, Lipworth BJ, Reid P, Smith RP, Ramage L, Ingram CG, et al. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax 1996; 51(7):689-693. Epub 1996/07/01.
8. Casaburi R, Kukafka D, Cooper CB, Witek TJ, Jr., Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127(3):809-817. Epub 2005/03/15.
9. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26(2):214-222. Epub 2005/08/02.
10. Cazzola M, Centanni S, Santus P, Verga M, Mondoni M, di Marco F, et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 2004; 98(12):1214-1221. Epub 2004/12/14.
11. Cazzola M, Biscione GL, Pasqua F, Crigna G, Appodia M, Cardaci V, et al. Use of 6-min and 12-min walking test for assessing the efficacy of formoterol in COPD. Respir Med 2008; 102(10):1425-1430. Epub 2008/07/16.
12. Wang J, Jin D, Zuo P, Wang T, Xu Y, Xiong W. Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis. Respirology 2010; 16(2):350-358. Epub 2010/12/09.
13. Beier J, Beeh KM. Long-acting beta-adrenoceptor agonists in the management of COPD: focus on indacaterol. Int J Chron Obstruct Pulmon Dis 2011; 6:237-243.
14. Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182(2):155-162.
15. Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ, Jr., et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122(1):47-55. Epub 2002/07/13.
16. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Molken MP, Beeh KM, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364(12):1093-1103. Epub 2011/03/25.
17. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Zaagsma J, Mueller A, et al. Combining tiotropium and salmeterol in COPD: Effects on airfl ow obstruction and symptoms. Respir Med 2010; 104(7):995-1004. Epub 2010/03/23.
18. Barker AF. Bronchiectasis. N Engl J Med 2002; 346(18):1383-1393. Epub 2002/05/03.
19. de Torres JP, Pinto-Plata V, Ingenito E, Bagley P, Gray A, Berger R, et al. Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD. Chest 2002; 121(4):1092-1098. Epub 2002/04/12.
20. Spruit MA, Polkey MI, Celli B, Edwards LD, Watkins ML, Pinto-Plata V, et al. Predicting Outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. J Am Med Dir Assoc 2012; 13(3):291-297. Epub 2011/07/23.
21. Cote CG, Pinto-Plata V, Kasprzyk K, Dordelly LJ, Celli BR. The 6-min walk distance, peak oxygen uptake, and mortality in COPD. Chest 2007; 132(6):1778-1785. Epub 2007/10/11.
22. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23(6):932-946. Epub 2004/06/29.
23. Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959; 2(5147):257-266. Epub 1959/08/29.
24. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988; 93(3):580-586. Epub 1988/03/01.
25. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005; 26(2):319-338. Epub 2005/08/02.
26. Crapo RO. The role of reference values in interpreting lung function tests. Eur Respir J 2004; 24(3):341-342. Epub 2004/09/11.
27. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123(6):659-664. Epub 1981/06/01.
28. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airfl ow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350(10):1005-1012. Epub 2004/03/05.
29. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airfl ow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145(6):1321-1327. Epub 1992/06/01.
30. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002; 19(3):398-404. Epub 2002/04/09.
31. Hills M, Armitage P. The two-period cross-over clinical trial. 1979. Br J Clin Pharmacol 2004; 58(7):S703-5716; discussion S17-9. Epub 2004/12/15.
32. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176(6):532-555. Epub 2007/05/18.
33. Holland AE, Hill CJ, Rasekaba T, Lee A, Naughton MT, McDonald CF. Updating the minimal important difference for six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil 2010; 91(2):221-225.
34. Polkey MI, Spruit MA, Edwards LD, Watkins ML, Pinto-Plata V, Vestbo J et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Study Investigators. Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med 2013; 187:382-386.
35. Fujimoto K, Kitaguchi Y, Kanda S, Urushihata K, Hanaoka M, Kubo K. Comparison of efficacy of long-acting bronchodilators in emphysema dominant and emphysema nondominant chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2011; 6:219-227. Epub 2011/06/11.
36. Okudan N, Gok M, Gokbel H, Suerdem M. Single dose of tiotropium improves the 6-minute walk distance in chronic obstructive pulmonary disease. Lung 2006; 184(4):201-204. Epub 2006/09/29.
37. Verkindre C, Bart F, Aguilaniu B, Fortin F, Guerin JC, Le Merre C, et al. The effect of tiotropium on hyperinfl ation and exercise capacity in chronic obstructive pulmonary disease. Respiration 2006; 73(4):420-427. Epub 2006/02/18.
38. Berton DC, Reis M, Siqueira AC, Barroco AC, Takara LS, Bravo DM, et al. Effects of tiotropium and formoterol on dynamic hyperinfl ation and exercise endurance in COPD. Respir Med 2010; 104(9):1288-1296.
39. Canto ND, Ribeiro J P, Neder JA, Chiappa GR. Addition of tiotropium to formoterol improves inspiratory muscle strength after exercise in COPD. Respir Med 2012; 106(10):1404-1412.
40. Garcia-Rio F, Lores V, Mediano O, Rojo B, Hernanz A, Lopez-Collazo E, et al. Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with dynamic hyperinfl ation. Am J Respir Crit Care Med 2009; 180(6):506-512. Epub 2009/06/23.
41. Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest 2001; 119(1):256-270. Epub 2001/02/07.
42. Cote CG, Celli BR. Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J 2005; 26(4):630-636. Epub 2005/10/06.
43. Cote CG, Pinto-Plata VM, Marin JM, Nekach H, Dordelly LJ, Celli BR. The modified BODE index: Validation with mortality in COPD. Eur Respir J 2008; 32(5):1269-1274. Epub 2008/06/27.
44. Cote CG, Celli BR. BODE index: a new tool to stage and monitor progression of chronic obstructive pulmonary disease. Pneumonol Alergol Pol 2009; 77(3):305-313. Epub 2009/07/11.
45. Karner C, Cates CJ. Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 4:CD008989. Epub 2012/04/20.
46. Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B, Celli BR. Inspiratory capacity, dynamic hyperinfl ation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163(6):1395-1399.
47. O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, et al. Effects of tiotropium on lung hyperinfl ation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23(6):832-840.
48. Calverley PM. Dynamic hyperinfl ation: is it worth measuring? Proc Am Thorac Soc 2006; 3(3):239-244.
49. Guenette JA, Webb KA, O'Donnell DE. Does dynamic hyperinfl ation contribute to dyspnoea during exercise in patients with COPD? Eur Respir J 2012; 40(2):322-329.